Concepts (163)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cathepsin B | 11 | 2022 | 35 | 5.710 |
Why?
|
| Macrophages | 16 | 2025 | 515 | 4.370 |
Why?
|
| HIV-1 | 15 | 2024 | 747 | 2.750 |
Why?
|
| HIV Infections | 17 | 2024 | 2535 | 2.590 |
Why?
|
| AIDS Dementia Complex | 8 | 2019 | 116 | 2.360 |
Why?
|
| Proteomics | 9 | 2025 | 363 | 2.230 |
Why?
|
| Cystatin B | 6 | 2022 | 11 | 1.730 |
Why?
|
| Neurons | 7 | 2022 | 1246 | 1.600 |
Why?
|
| Cannabinoids | 2 | 2024 | 67 | 1.490 |
Why?
|
| Apoptosis | 10 | 2025 | 1541 | 1.130 |
Why?
|
| Cognition Disorders | 6 | 2017 | 243 | 0.970 |
Why?
|
| Proteome | 3 | 2021 | 150 | 0.950 |
Why?
|
| Virus Replication | 5 | 2022 | 318 | 0.790 |
Why?
|
| Monocytes | 6 | 2013 | 275 | 0.730 |
Why?
|
| Receptor, Cannabinoid, CB2 | 1 | 2022 | 34 | 0.720 |
Why?
|
| Severity of Illness Index | 1 | 2024 | 708 | 0.710 |
Why?
|
| Antioxidants | 2 | 2018 | 439 | 0.700 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2021 | 112 | 0.640 |
Why?
|
| Endoribonucleases | 1 | 2019 | 24 | 0.610 |
Why?
|
| Ethylenediamines | 1 | 2018 | 8 | 0.590 |
Why?
|
| Receptors, sigma | 1 | 2018 | 16 | 0.590 |
Why?
|
| Cocaine | 2 | 2018 | 248 | 0.570 |
Why?
|
| Humans | 29 | 2025 | 42163 | 0.560 |
Why?
|
| Anabolic Agents | 1 | 2017 | 19 | 0.540 |
Why?
|
| Neoplasm Proteins | 1 | 2019 | 228 | 0.530 |
Why?
|
| Hypothalamus | 1 | 2017 | 121 | 0.510 |
Why?
|
| Androgens | 1 | 2017 | 107 | 0.510 |
Why?
|
| Female | 21 | 2025 | 24018 | 0.510 |
Why?
|
| Interferon-beta | 1 | 2016 | 9 | 0.500 |
Why?
|
| STAT1 Transcription Factor | 1 | 2016 | 35 | 0.490 |
Why?
|
| Tandem Mass Spectrometry | 3 | 2024 | 230 | 0.480 |
Why?
|
| Cells, Cultured | 5 | 2019 | 1617 | 0.470 |
Why?
|
| Oxidative Stress | 4 | 2025 | 990 | 0.470 |
Why?
|
| Host-Pathogen Interactions | 1 | 2016 | 203 | 0.440 |
Why?
|
| Cell Line | 4 | 2019 | 1416 | 0.420 |
Why?
|
| Cocaine-Related Disorders | 1 | 2014 | 99 | 0.420 |
Why?
|
| HIV Seropositivity | 2 | 2013 | 196 | 0.410 |
Why?
|
| Microglia | 1 | 2015 | 204 | 0.400 |
Why?
|
| NF-kappa B | 2 | 2025 | 355 | 0.360 |
Why?
|
| Placenta | 2 | 2022 | 113 | 0.350 |
Why?
|
| Cerebrospinal Fluid | 2 | 2007 | 20 | 0.350 |
Why?
|
| Flow Cytometry | 3 | 2019 | 411 | 0.330 |
Why?
|
| HIV Core Protein p24 | 2 | 2018 | 11 | 0.300 |
Why?
|
| Lysosomes | 2 | 2024 | 88 | 0.300 |
Why?
|
| Glutathione Peroxidase | 1 | 2008 | 100 | 0.290 |
Why?
|
| Catalase | 1 | 2008 | 111 | 0.290 |
Why?
|
| Caspase 3 | 2 | 2019 | 226 | 0.280 |
Why?
|
| Superoxide Dismutase | 1 | 2008 | 158 | 0.280 |
Why?
|
| Culture Media, Conditioned | 2 | 2019 | 49 | 0.270 |
Why?
|
| Up-Regulation | 2 | 2025 | 534 | 0.270 |
Why?
|
| Adult | 12 | 2024 | 13458 | 0.260 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2018 | 138 | 0.260 |
Why?
|
| Cohort Studies | 5 | 2017 | 1729 | 0.260 |
Why?
|
| Pregnancy | 2 | 2022 | 1737 | 0.250 |
Why?
|
| Phagosomes | 1 | 2025 | 33 | 0.230 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2025 | 16 | 0.230 |
Why?
|
| Blotting, Western | 3 | 2017 | 884 | 0.230 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2025 | 64 | 0.230 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2025 | 128 | 0.220 |
Why?
|
| Blood-Brain Barrier | 2 | 2019 | 167 | 0.220 |
Why?
|
| Cisplatin | 1 | 2025 | 91 | 0.220 |
Why?
|
| Middle Aged | 9 | 2024 | 11819 | 0.220 |
Why?
|
| Cystatin C | 2 | 2015 | 25 | 0.210 |
Why?
|
| Exocytosis | 1 | 2024 | 49 | 0.210 |
Why?
|
| Blood Proteins | 1 | 2024 | 75 | 0.210 |
Why?
|
| Hippocampus | 2 | 2019 | 591 | 0.190 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2025 | 290 | 0.190 |
Why?
|
| Puerto Rico | 3 | 2024 | 1376 | 0.190 |
Why?
|
| Profilins | 1 | 2022 | 2 | 0.190 |
Why?
|
| Analysis of Variance | 2 | 2017 | 574 | 0.190 |
Why?
|
| Serum Amyloid P-Component | 1 | 2022 | 21 | 0.180 |
Why?
|
| Mice | 4 | 2025 | 6490 | 0.180 |
Why?
|
| Fibrinogen | 1 | 2021 | 24 | 0.180 |
Why?
|
| Transfection | 2 | 2016 | 526 | 0.170 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2021 | 78 | 0.170 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 3 | 2010 | 78 | 0.170 |
Why?
|
| Ovarian Neoplasms | 1 | 2025 | 406 | 0.170 |
Why?
|
| Young Adult | 2 | 2024 | 4936 | 0.170 |
Why?
|
| Extracellular Matrix | 1 | 2021 | 129 | 0.170 |
Why?
|
| Viral Load | 3 | 2013 | 344 | 0.160 |
Why?
|
| Cytokines | 1 | 2024 | 661 | 0.160 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2012 | 167 | 0.160 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 2019 | 7 | 0.160 |
Why?
|
| Synaptophysin | 1 | 2019 | 6 | 0.160 |
Why?
|
| Neuropsychological Tests | 2 | 2013 | 281 | 0.150 |
Why?
|
| Histidine | 1 | 2019 | 44 | 0.150 |
Why?
|
| Mice, Inbred ICR | 1 | 2018 | 43 | 0.150 |
Why?
|
| Reactive Nitrogen Species | 1 | 2018 | 10 | 0.150 |
Why?
|
| Morpholines | 1 | 2018 | 73 | 0.140 |
Why?
|
| Transcription Factors | 1 | 2022 | 722 | 0.140 |
Why?
|
| Longitudinal Studies | 2 | 2013 | 1020 | 0.140 |
Why?
|
| Microwaves | 1 | 2017 | 27 | 0.140 |
Why?
|
| Magnetics | 1 | 2017 | 43 | 0.130 |
Why?
|
| Inflammation | 1 | 2022 | 729 | 0.130 |
Why?
|
| Cell Line, Tumor | 3 | 2025 | 2598 | 0.130 |
Why?
|
| Antineoplastic Agents | 1 | 2025 | 979 | 0.130 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2015 | 229 | 0.130 |
Why?
|
| Chromatography, Liquid | 1 | 2017 | 173 | 0.120 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 928 | 0.120 |
Why?
|
| Neuronal Plasticity | 1 | 2017 | 126 | 0.120 |
Why?
|
| Apolipoprotein C-III | 1 | 2015 | 7 | 0.120 |
Why?
|
| Synapses | 1 | 2017 | 184 | 0.120 |
Why?
|
| Animals | 4 | 2025 | 16695 | 0.120 |
Why?
|
| Reactive Oxygen Species | 1 | 2018 | 518 | 0.120 |
Why?
|
| Protein Transport | 1 | 2016 | 295 | 0.120 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2015 | 196 | 0.110 |
Why?
|
| Cell Nucleus | 1 | 2016 | 383 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 1112 | 0.110 |
Why?
|
| Male | 4 | 2024 | 22779 | 0.110 |
Why?
|
| Nervous System | 1 | 2014 | 33 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 456 | 0.100 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 436 | 0.100 |
Why?
|
| Phosphorylation | 1 | 2016 | 973 | 0.100 |
Why?
|
| Basal Ganglia | 1 | 2012 | 20 | 0.100 |
Why?
|
| Signal Transduction | 2 | 2025 | 2111 | 0.100 |
Why?
|
| Intracellular Space | 1 | 2012 | 37 | 0.090 |
Why?
|
| DNA, Viral | 1 | 2013 | 323 | 0.090 |
Why?
|
| Aged | 1 | 2024 | 7982 | 0.090 |
Why?
|
| Lymphocytes | 2 | 2013 | 124 | 0.090 |
Why?
|
| Immunologic Techniques | 1 | 2010 | 12 | 0.090 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 1066 | 0.080 |
Why?
|
| Peroxiredoxins | 1 | 2010 | 10 | 0.080 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2010 | 102 | 0.080 |
Why?
|
| Brain | 1 | 2018 | 1452 | 0.080 |
Why?
|
| Chromatography, Affinity | 1 | 2010 | 67 | 0.080 |
Why?
|
| Peroxidase | 1 | 2010 | 57 | 0.080 |
Why?
|
| Free Radical Scavengers | 1 | 2010 | 63 | 0.080 |
Why?
|
| Thioredoxins | 1 | 2010 | 36 | 0.080 |
Why?
|
| Disease Progression | 1 | 2013 | 661 | 0.080 |
Why?
|
| Mass Spectrometry | 2 | 2007 | 279 | 0.080 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 3077 | 0.070 |
Why?
|
| Confidence Intervals | 1 | 2008 | 162 | 0.070 |
Why?
|
| Cognition | 1 | 2012 | 458 | 0.070 |
Why?
|
| Molecular Sequence Data | 2 | 2007 | 1559 | 0.070 |
Why?
|
| Receptors, CCR5 | 1 | 2007 | 64 | 0.070 |
Why?
|
| Receptors, CXCR4 | 1 | 2007 | 74 | 0.070 |
Why?
|
| Virulence | 1 | 2007 | 238 | 0.060 |
Why?
|
| Glioma | 1 | 2007 | 92 | 0.060 |
Why?
|
| Phenotype | 1 | 2007 | 774 | 0.050 |
Why?
|
| Protein Array Analysis | 1 | 2004 | 27 | 0.050 |
Why?
|
| Lipopolysaccharides | 1 | 2025 | 235 | 0.050 |
Why?
|
| Mice, Nude | 1 | 2025 | 403 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2007 | 683 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2025 | 339 | 0.050 |
Why?
|
| Down-Regulation | 1 | 2025 | 452 | 0.050 |
Why?
|
| Nitric Oxide | 1 | 2025 | 381 | 0.050 |
Why?
|
| United States | 1 | 2013 | 5072 | 0.050 |
Why?
|
| Retrospective Studies | 1 | 2008 | 2485 | 0.050 |
Why?
|
| Smoking | 1 | 2007 | 1019 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2025 | 933 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2025 | 1420 | 0.040 |
Why?
|
| Oxygen Isotopes | 1 | 2015 | 5 | 0.030 |
Why?
|
| Sampling Studies | 1 | 2013 | 64 | 0.030 |
Why?
|
| Complement C3 | 1 | 2007 | 16 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2007 | 198 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2007 | 200 | 0.020 |
Why?
|
| Hawaii | 1 | 2013 | 2004 | 0.020 |
Why?
|
| Wechsler Scales | 1 | 2006 | 7 | 0.020 |
Why?
|
| Women's Health | 1 | 2007 | 158 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 2007 | 182 | 0.020 |
Why?
|
| Memory | 1 | 2006 | 175 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2007 | 1188 | 0.010 |
Why?
|
| Prevalence | 1 | 2006 | 1597 | 0.010 |
Why?
|